View More Recent Stories

Mar 28, 2022 10:45AM Amylyx Pharmaceuticals Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on AMX0035
Mar 18, 2022 09:00AM Amylyx Pharmaceuticals Announces Launch of U.S. Expanded Access Program for AMX0035
Feb 25, 2022 08:08AM Amylyx Pharmaceuticals (AMLX) Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
Feb 25, 2022 08:00AM Amylyx Pharmaceuticals Announces EMA Validation of Marketing Authorisation Application (MAA) for AMX0035 for the Treatment of ALS
Feb 23, 2022 08:00AM Amylyx Pharmaceuticals Expands Executive Team with Appointment of Gina M. Mazzariello as Chief Legal Officer and General Counsel
Feb 16, 2022 04:05PM Amylyx Pharmaceuticals Announces FDA Advisory Committee Meeting to Review New Drug Application for AMX0035 for the Treatment of ALS Scheduled for March 30, 2022
Feb 10, 2022 08:00AM Amylyx Pharmaceuticals to Present at the 11th Annual SVB Leerink Global Healthcare Conference
Feb 3, 2022 08:03AM Amylyx Pharmaceuticals (AMLX) Partners with Canadian Neuromuscular Disease Registry on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outco
Feb 3, 2022 08:00AM The Canadian Neuromuscular Disease Registry and Amylyx Pharmaceuticals Partner on Real-World Evidence Generation for a Novel Investigational Therapy in ALS with the Goal of Advancing Health Outcomes f
View More Recent Stories